Business context and reporting period
IRIDEX Corporation develops, manufactures and markets ophthalmic laser systems, delivery devices and consumables for glaucoma and retinal diseases, as well as service and support. This unaudited Form 10-Q covers the 13-week second quarter and six months ended July 2, 2022; comparable periods ended July 3, 2021.
Financial performance and liquidity
Unless otherwise stated, amounts are in millions of dollars.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $13.755 | $13.426 | $27.142 | $25.385 |
| Gross profit / margin | $6.267 / 45.6% | $6.108 / 45.5% | $12.244 / 45.1% | $11.047 / 43.5% |
| Operating expenses | $8.427 | $7.246 | $16.681 | $14.026 |
| Operating loss | $(2.160) | $(1.138) | $(4.437) | $(2.979) |
| Net income (loss) | $(2.241) | $1.393 | $(4.632) | $(0.617) |
| Basic and diluted EPS | $(0.14) | $0.09 | $(0.29) | $(0.04) |
- For the six months, operating cash flow was $(5.823), investing cash flow $(0.146), and financing cash flow $(0.047); cash declined $5.886 to $17.966.
- At July 2, cash was $17.966 and working capital was $27.1, versus $23.852 and $29.6, respectively, at January 1, 2022. Total assets were $45.646 and stockholders’ equity $19.432.
- No borrowings were outstanding under the $8.0 million Silicon Valley Bank revolving facility. Its term was extended to December 1, 2023. Operating lease liabilities totaled $2.216.
- Non-cancellable purchase commitments were approximately $22.7 million through fiscal 2024, including $15.2 million due in the next 12 months.
- Deferred revenue was $14.907, including approximately $13.4 million related to Topcon exclusivity fees. The company recognized $0.3 million of exclusivity revenue in Q2 and $0.6 million in the first half.
Material changes versus prior comparable periods
- Revenue rose 2.5% in Q2 and 6.9% in the first half. First-half revenue growth came principally from Retina, service and legacy G-probe sales, and recognized Topcon distribution-rights revenue. Q2 Cyclo G6 revenue fell 3.4%, Retina was down 0.6%, and Other increased 22.1%.
- Gross margin improved 0.1 percentage point in Q2 and 1.6 points for the first half. Management attributed the improvement to favorable geographic mix, pricing discipline and exclusivity revenue.
- Operating expenses increased 16.3% in Q2 and 18.9% in the first half. Sales and marketing rose 26.4% and 34.4%, respectively, reflecting expanded programs; R&D rose 15.0% and 42.3%, driven by product development and PASCAL investment. First-half G&A declined 18.1%, mainly due to lower legal and consulting costs.
- Q2 shifted from prior-year net income to a net loss; the prior-year quarter included a $2.5 million PPP loan-forgiveness gain. The same gain contributed to the prior-year first-half result. Excluding that unusual comparison item, the filing does not provide a non-GAAP reconciliation.
- Operating cash flow swung from $10.599 provided in the prior-year first half to $5.823 used. The company cited the prior-year receipt of distribution fees, increased vendor payments to mitigate supply constraints, and higher payroll, partly offset by greater customer receipts.
Outlook, management commentary and risks
- Management said product demand remained and its outlook had improved, but hospital, surgery-center and physician-office capital spending remained uncertain; COVID-19 and other variants could continue to defer purchases. The filing provides no numerical revenue or earnings guidance.
- The company expects operating losses and negative operating cash flows to continue through July 1, 2023, while stating that existing cash should meet anticipated needs for at least the next 12 months. Additional financing may be needed if circumstances or spending differ from expectations.
- Topcon held a 10.2% voting interest and represented 26% of Q2 revenue and 28% of first-half revenue. The company is exposed to distributor performance and related-party concentration; Topcon is its exclusive distributor in certain international regions.
- Key risks include COVID-related demand and supply disruption, inflation and macroeconomic uncertainty, sole- or limited-source suppliers, production and product-quality issues, international and currency exposure, competition, regulatory and reimbursement requirements, and execution of product development and the Topcon partnership.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level, with no material change in internal control over financial reporting during the quarter. Ordinary-course legal matters were not expected to have a material adverse effect. The filing also notes a pending request to terminate the 2018 TruFocus LIO Premiere recall.
Important facts for investors to verify
- Whether revenue growth and gross-margin improvement persist without reliance on deferred Topcon exclusivity revenue, and whether operating expenses translate into sustained growth.
- Cash burn, inventory buildup (up to $10.176 million from $7.614 million at year-end), and the ability to fund operations alongside $15.2 million of near-term purchase commitments.
- Topcon’s sales performance, receivable collection and the effect of its significant share of revenue; confirm the terms and covenants of the amended bank facility.
- Whether supply constraints, COVID-related procedure delays, and capital-spending deferrals affect demand, shipments and future cash flows.
- The status and potential consequences of the TruFocus LIO recall-termination request and any material changes in product, regulatory or litigation matters.